Statins in Hypertensive Patients: Potential Explanations for the ASCOT-LLA Study Results

Sever P, Dahlof B, Poulter N. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo—Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–58 Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020–5 Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131–4 Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450–7 O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–31 John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98: 211–6 Loscalzo J. Pathogenesis of thrombosis. In: Beutler E, Lichtman MA, Coller BS, et al. editors. Williams Hematology. 5th ed. New York: McGraw-Hill, 1995: 1525–30 Panza JA, Garcia CE, Kilcoyne CM, et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995; 91: 1732–8 Lewis TV, Dart AM, Chin-Dusting JPF. Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. J Am Coll Cardiol 1999; 33: 805–12 Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly supresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146–54 Hernández-Perera O, Pérez-Sala D, Soria D, et al. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87: 616–22 Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996; 18: 669–75 Seljeflot I, Tonstad S, Hjermann I, et al. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002; 162: 179–85 Sata M, Walsh K. TNF-α regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nature Med 1998; 4: 415–20 Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189–92 Blanco-Colio LM, Martín-Ventura JL, Sol JM, et al. Decreased circulating Fas Ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis. Normalization by atorvastatin. J Am Coll Cardiol 2004; 43: 1188–94 Ruiz-Ortega M, Ruperez M, Esteban V, et al. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003; 5: 73–9 Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86: 1266–72 Takemoto M, Liao J. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Arterioscler Thromb Vasc Biol 2001; 21: 1712–9 Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881–900 Grimm S, Baeuerle. The inducible transcription factor NF-κB: structure—function relationship of its protein subunits. Biochem J 1993; 290: 297–308 Barnes PJ, Karin M. Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. N Eng J Med 1997; 336: 1066–71 Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997; 272: 15817–24 Brand K, Page S, Rogler G, et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715–22 Martin-Ventura JL, Blanco-Colio LM, Muñoz-Garcia B, et al. NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke 2004; 35: 458–63 Ortego M, Bustos C, Hernández-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253–61 Bustos C, Hernández-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057–64 Hernández-Presa MA, Ortego M, Tuñón J, et al. Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 2003; 57: 168–77 Hernández-Presa MA, Martín-Ventura JL, Ortego M, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002; 160: 49–58 Shiomi M, Ito T. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipids levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999; 126: 961–8 Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, supresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276–83 Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926–33 Martin-Ventura JL, Blanco-Colio LM, Muñoz-Garcia B, et al. Intensive treatment with atorvastatin reduces blood and plaque inflammation in patients with atherosclerotic lesions in one month [abstract]. Circulation 2003; 108 Suppl IV: 22 Di Napoli M, Papa F. Association between blood preassure and C-reactive protein levels in acute ischemic stroke. Hypertension 2003; 42: 1117–23 Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959–65 Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933–5 Gómez-Gerique JA, Ros E, Olivan J, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002; 162; 245–51 Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839–44 Bourcier T, Libby P. HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556–62 Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/ Rho kinase and Akt pathways. Circulation 2002; 105: 1756–9 Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294–304 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007 Hennekens CH. The ALLHAT-LLT and ASCOT-LLA trials: are the discrepancies more apparent than real?. Curr Atheroscler Rep 2004; 6: 9–11